# Intravascular Imaging-Guided Versus Angiography-Guided PCI:

# **Systematic Review and Meta-analysis of 24 Randomized Controlled Trials**

- David Hong, MD<sup>1\*</sup>, Woochan Kwon, MD<sup>1\*</sup>, Seung Hun Lee, MD, PhD<sup>2†</sup>, Doosup Shin, MD<sup>3</sup>, 4
- 5 Hyun Kuk Kim, MD, PhD<sup>4</sup>, Kwan Yong Lee, MD, PhD<sup>5</sup>, Eun Ho Choo, MD, PhD<sup>5</sup>, Sung Eun
- Kim, MD<sup>6</sup>, Young Joon Hong, MD, PhD<sup>2</sup>, Young Keun Ahn, MD, PhD<sup>2</sup>, Myung Ho Jeong, 6
- MD, PhD<sup>2</sup>, Junho Ha, MD<sup>1</sup>, Minseok Hong, MD<sup>1</sup>, Ki Hong Choi, MD, PhD<sup>1</sup>, Taek Kyu Park, 7
- MD, PhD<sup>1</sup>, Jeong Hoon Yang, MD, PhD<sup>1</sup>, Young Bin Song, MD, PhD<sup>1</sup>, Joo-Yong Hahn, MD, 8
- PhD<sup>1</sup>, Seung-Hyuk Choi, MD, PhD<sup>1</sup>, Hyeon-Cheol Gwon, MD, PhD<sup>1</sup>, Joo Myung Lee, MD, 9
- MPH, PhD<sup>1†</sup>, The RENOVATE COMPLEX-PCI Investigators 10
- \* DH and WK contributed equally as the first authors. 12

1

2

3

11

14

22

- † SHL and JML contributed equally as the corresponding authors. 13
- <sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 15
- <sup>2</sup>Department of Internal Medicine and Cardiovascular Center, Chonnam National University 16
- Hospital, Gwangju, Korea; <sup>3</sup>Division of Cardiology, Department of Internal Medicine, Duke 17
- University Medical Center, Durham, NC, USA; <sup>4</sup>Department of Internal Medicine and 18
- Cardiovascular Center, Chosun University Hospital, University of Chosun College of Medicine, 19
- Gwangju, Korea; <sup>5</sup>Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; 20
- <sup>6</sup>Department of Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. 21
- Running title: A Meta-analysis of Intravascular Imaging-Guided PCI 23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Word count:** 2

1

6

- 3 Manuscript – 3,584 (not including abstract, tables, figures, acknowledgments, references, and
- online-only material) 4
- Number of Tables and Figures 1/5 5
- 7 Address for correspondence:
- 8 Seung Hun Lee, MD, PhD
- Division of Cardiology, Department of Internal Medicine, Chonnam National University 9
- 10 Hospital, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju
- 11 61469, Republic of Korea
- Tel; 82-10-6413-7449, Fax; 82-2-6455-1449 12
- E-mail; lsh8602@naver.com, gfmaniac@gmail.com 13
- Joo Myung Lee, MD, MPH, PhD 15
- 16 Department of Internal Medicine and Cardiovascular Center,
- Heart Vascular Stroke Institute, Samsung Medical Center, 17
- 50, Irwon-dong, Gangnam-gu, Seoul 135–710, Republic of Korea 18
- 19 Telephone: 82-2-3410-3391; Fax: 82-2-3410-6278
- 20 E-mail: drone80@hanmail.net, joomyung.lee@samsung.com

#### **Abstract**

- **Objective:** To evaluate comparative prognosis between intravascular imaging-guided PCI and 2
- 3 angiography-guided PCI using a comprehensive meta-analysis including all previous
- randomized controlled trials. 4
- **Design**: Systematic review and meta-analysis of randomized controlled trials. 5
- Data Sources: Target trials were selected by a systematic electronic search strategy in the 6
- 7 PubMed, EMBASE, and Cochrane databases from their inception to Sep, 2023.
- 8 **Study Selection:** Published randomized controlled trials which compared clinical outcomes
- 9 between intravascular imaging-guided and angiography-guided PCI were included.
- Main Outcome and Measures: Major adverse cardiac events (MACE), all-cause death, 10
- 11 myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis.
- Review Methods: Random-effects model was used to calculate pooled relative risk (RR) and 12
- 95% confidence interval (CI) between intravascular imaging-guided and angiography-guided 13
- PCI. Heterogeneity was assessed by I<sup>2</sup> values. 14
- Results: Among a total of 14,037 patients (7,383 in intravascular imaging-guided PCI and 15
- 16 6,654 in angiography-guided PCI groups), intravascular imaging-guided PCI was associated
- with a lower risk of MACE than angiography-guided PCI (RR, 0.75; 95% CI, 0.67 to 0.84; 17
- P<0.001; I<sup>2</sup>, 18.9%), driven by lower risk of MI (RR, 0.83; 95% CI, 0.70 to 0.97; P=0.019; I<sup>2</sup>, 18
- 0.0%), TVR (RR, 0.70; 95% CI, 0.61 to 0.79; P<0.001; I<sup>2</sup>, 0.0%), and stent thrombosis (RR, 19
- 0.50; 95% CI, 0.32 to 0.78; P=0.002; I<sup>2</sup>, 0.0%). There was no difference in the risk of all-cause 20
- death (RR, 0.82; 95% CI, 0.67 to 1.01; P=0.068; I<sup>2</sup>, 0.0%), however, trials with 2<sup>nd</sup> generation 21
- 22 drug-eluting stent (DES) showed significant reduction of all-cause death following
- intravascular imaging-guided PCI (RR, 0.77; 95% CI, 0.61 to 0.95; P=0.018; I<sup>2</sup>, 0.0%). 23

- Conclusions: Compared to angiography-guided PCI, intravascular imaging-guided PCI was 1
- associated with a reduced the risk of MACE, by lowering the risks of MI, TVR, and stent 2
- 3 thrombosis. Pooled analysis of trials with 2<sup>nd</sup> generation DES showed significantly lower risk
- 4 of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI.
- Systematic Review Registration: PROSPERO, CRD42023402677 6
- Key Words: Coronary artery disease; Percutaneous coronary intervention; Intravascular 8
- ultrasound; Optical coherence tomography; Meta-analysis. 9

5

### **Summary Boxes**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

## What is already known on this topic

- Due to limited sample size, previous randomized controlled trials (RCTs) were not able to show significant differences in the risks of hard clinical events such as death, myocardial infarction (MI), or stent thrombosis between intravascular imagingguided percutaneous coronary intervention (PCI) and angiography-guided PCI.
  - Although previous meta-analyses showed that intravascular imaging-guided PCI resulted in a lower risk of death or MI than angiography-guided PCI, inclusion of both observational studies and RCTs caused heterogeneity and lowered the evidence level of the results.

### What this study adds

- The current meta-analysis exclusively included 24 RCTs and showed that intravascular imaging-guided PCI significantly reduced the risk of major adverse cardiac events (MACE), compared with angiography-guided PCI.
- It should be noted that intravascular imaging-guided PCI reduced not only the risk of target-vessel revascularization but also the risks of hard clinical events such as MI and stent thrombosis.

## **Abbreviations**

1

- CI = confidence interval 2
- 3 DES = drug-eluting stent
- IVUS = intravascular ultrasound 4
- 5 MACE = major adverse cardiac events
- 6 MI = myocardial infarction
- 7 OCT = optical coherence tomography
- 8 OR = odds ratio
- 9 PCI = percutaneous coronary intervention
- RCT = randomized controlled trial 10
- 11 TVR = target vessel revascularization

## Introduction

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Percutaneous coronary intervention (PCI) is one of the important treatment options for patients with coronary artery stenosis. Despite improvement of drug-eluting stent (DES) platforms and PCI techniques, it is still unclear whether PCI can reduce death or myocardial infarction (MI) compared with guideline-directed medical treatment alone, <sup>1</sup> <sup>2</sup> and PCI for complex coronary artery lesions is challenging in daily practice due to increased risk of stent failure.<sup>3-5</sup> Therefore, continuous efforts have been made to find how to guide and optimize PCI to improve clinical outcomes. In this regard, intravascular imaging using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) would be useful by providing information on lesion characteristics, reference vessel size, stent expansion and apposition, and acute complications.6 Previous randomized controlled trials (RCTs) have shown lower rates of major adverse cardiac events (MACE) after intravascular imaging-guided PCI than after angiography-guided PCI,<sup>7-28</sup> although it mainly reduced the risk of repeat revascularization without significant difference in hard clinical events such as death, MI, or stent thrombosis. In contrast, the recently published RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) firstly demonstrated a superiority of intravascular imaging-guided PCI over angiography-guided PCI in patients with complex coronary artery lesions, mainly driven by reduced risk of cardiac death and MI with intravascular imaging guidance. The OCTOBER (European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction) trial also showed the prognostic benefit of OCT-guided PCI over angiography-guided PCI in patients with complex bifurcation lesions.<sup>29</sup> Conversely, ILUMIEN IV (OPtical Coherence Tomography [OCT] Guided Coronary Stent IMplantation Compared to

7 m ng.ne recerred reces anoned mareat permission

1 Angiography: a Multicenter Randomized TriaL in PCI) failed to show significant difference in

target vessel failure between the two strategies in patients with diabetes mellitus or complex

coronary artery lesions.<sup>30</sup>

Therefore, we conducted an updated meta-analysis using all available RCTs to date to

investigate whether intravascular imaging-guided PCI would improve clinical outcomes

compared with angiography-guided PCI.

#### Methods

#### **Data Sources and Searches**

PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes of Health registry of clinical trials, and relevant websites were searched for pertinent published or unpublished studies from inception to September 2023. The electronic search strategy was complemented by manual examination of references cited by included articles, recent reviews, editorials, and meta-analyses. No restrictions were imposed on study period or sample size, but only articles in English were considered. Keywords included 'intravascular ultrasound, 'optical coherence tomography', 'PCI', 'percutaneous coronary intervention', 'coronary stenting', 'stenting', 'stent', 'stent implantation', 'angiography', 'impact', 'outcome', 'randomized', and 'randomized clinical trial' (**Supplemental Table 1**). The present study complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>31</sup> The study protocol was prespecified and registered with PROSPERO (CRD42023402677). Institutional Review Board (IRB) of Samsung Medical Center waived IRB approval process based on the study design, which is the study-level meta-analysis using published materials.

### **Study Selection**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Studies were included if they met the following prespecified criteria: (1) RCTs comparing intravascular imaging-guided PCI versus angiography-guided PCI in patients with coronary artery disease; (2) clinical outcome assessment with follow-up duration of at least 1 month; and (3) clinical outcomes including all-cause death, cardiac death, MI, target vessel revascularization (TVR), or stent thrombosis. Non-randomized studies, duplicated reports of previous RCTs, or post-hoc analysis including cost-effectiveness analysis of reported RCTs were not included (Supplemental Table 2). Two independent investigators (D.H. and W.K.) screened titles and abstracts, identified duplicates, performed full-article reviews, and determined inclusion. Two other investigators (S.H.L. and J.M.L.) supervised the search and adjudicated disagreements.

## **Data Extraction and Quality Assessment**

Summary data as reported in the published manuscripts were analyzed. A standardized form was used to extract study characteristics; trial design; number of trial population; median follow-up duration; type of intravascular imaging devices; demographics; clinical and angiographic eligibility criteria, including clinical diagnosis and angiographic lesion characteristics; proportion of cardiovascular risk factors; and used stent types. The rates of allcause mortality, MI, TVR, stent thrombosis, and MACE were collected, along with the definition of clinical events, as reported on an intention-to-treat basis. For trials which used both IVUS and OCT, group size and number of events were separately extracted, according to the type of intravascular imaging devices. In trials with available reports for both short- and long-term clinical outcomes, those with the longest follow-up duration were used in the current meta-analysis. In addition, unadjusted results of clinical events were used in the current meta-

analysis.

1

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

The quality of eligible trials was assessed using the Cochrane Collaborations tool 2

Version 2 for assessing the risk of bias in RCTs regarding random sequence generation,

allocation concealment, blinding of participants and outcome assessment, incomplete outcome

assessment, or selective reporting. We did not exclude individual studies from the analysis

based on the risk of bias in RCTs.

#### **Outcomes and Definitions**

The primary outcome was MACE at the longest available follow-up. Since the definition of MACE or composite outcomes varied across the trials, we used representative composite outcome reported under intention-to-treat principle in the included trials. The definition of MACE used in the included trials are presented in **Supplemental Table 3**. In most trials, MACE was a composite of all-cause death, MI, and TVR. Secondary outcomes included all-cause death, MI, TVR, and stent thrombosis.

#### **Data Synthesis and Analysis**

Primary and secondary outcomes were analyzed using random-effects models. Relative risks (RRs) with 95% confidence intervals (CIs) were presented as summary statistics. Because all included studies showed heterogeneity regarding study protocol and populations, fixed-effects models were only used for sensitivity analyses to check whether these models yielded similar results. The pooled RRs and 95% confidence intervals were calculated using the DerSimonian and Laird method for random effects, as well as the Mantel-Haenszel method for fixed effects. Because of progressive changes in primary study designs and clinical practice patterns, especially type of used stents (bare metal stent, 1st or 2nd generation DES), we

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

evaluated the impact of publication date on the overall effect of pooled RRs for the risk of MACE by a cumulative meta-analysis. Since all of the included trials in the cumulative metaanalysis had the same comparison groups, cumulative pooled effect estimates up to time point of last study inclusion could reflect temporal trends in effect size (RR). Statistical heterogeneity was quantified with the I<sup>2</sup> statistics. I<sup>2</sup> values <25%, 25% to 50%, and >50% indicate low, moderate, and high degrees of heterogeneity, respectively. Small study bias (publication bias) was assessed by funnel plot asymmetry and Egger's and Begg's tests; when visual asymmetry of funnel plot was suspected, the trim-and-fill method was used to estimate the number of missing studies and to calculate a corrected RR, as if these studies were present. The influence of an individual study was explored by estimating pooled RRs, with stepwise exclusion of one study. Subgroup analyses were performed to determine whether effects differed across subgroups. These subgroups analyses were analyzed: (1) type of intravascular imaging devices (IVUS or OCT); (2) angiographic characteristics (all-comers population or patients with complex coronary artery disease); (3) type of complex coronary artery lesions (chronic total occlusion, left main disease, or diffuse long lesion); (4) type of used stents (bare metal stent, 1st or 2nd generation DES); (5) clinical presentation (stable ischemic heart disease or acute coronary syndrome); and (6) presence of cardiovascular risk factors (diabetes mellitus or chronic kidney disease). Random-effects meta regression analysis was performed to evaluate differential effect size of intravascular imaging-guided PCI for MACE according to each subgroup. Two-sided P-values <0.05 were considered statistically significant. Statistical analysis was performed using STATA/SE 12.0 (Stata Corp LP, College Station, Texas, USA) and R programming language, version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

#### **Results**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

#### **Included Trials and Patient Characteristics**

Of a total of 809 searched articles, 38 were retrieved for full article review and 24 met prespecified inclusion criteria and were finally included (Figure 1). A total of 14,037 patients from 24 RCTs were included in the current meta-analysis. Among the total patients, 7,383 (52.6%) patients were treated with intravascular imaging-guided PCI and the remaining 6,654 (47.4%) patients were with angiography-guided PCI. The characteristics of the included trials are summarized in **Table 1**. The study population of 11 trials were all-comers without restriction by angiographic lesion characteristics and the remaining 13 trials exclusively enrolled patients with complex coronary artery lesions. Fifteen trials exclusively used IVUS, 6 trials exclusively used OCT, and the other 3 trials used both IVUS and OCT. 17 trials used 2<sup>nd</sup> generation DES and the other 7 trials used bare metal stent or 1st generation DES. The followup duration of each trial ranged from 6 months to 5 years and weighted median follow-up duration in the current meta-analysis was 2.0 years. Regarding the quality of included trials, most trials were deemed to be at low risk of bias, although some criteria were unclearly described in few trials (Supplemental Figure 1 and Supplemental Table 4). The characteristics of patients in the included trials are presented in **Supplemental Table 5**. Briefly, weighted mean age of the study population was 64.3 years and 75.6% were male. 64.8%, 30.5%, and 60.4% of the study population had hypertension, diabetes mellitus, and dyslipidemia, respectively. 55.7% of the study population presented with acute coronary syndrome. As only RCTs were included in the current study, baseline characteristics were balanced between intravascular imaging-guided PCI and angiographyguided PCI groups.

## **Clinical Outcomes**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Among 14,037 patients from 24 RCTs, observed rates of MACE in pooled analysis were 9.1% and 12.4% at a weighted median follow-up of 2.0 years for intravascular imagingguided PCI and angiography-guided PCI groups, respectively. In random-effects model, intravascular imaging-guided PCI was associated with a lower risk of MACE than angiography-guided PCI (RR, 0.75; 95% CI, 0.67 to 0.84; P<0.001; heterogeneity I<sup>2</sup>, 18.9%) (Figure 2). Number needed to treat to prevent one MACE was 33 (95% CI, 25 to 50). A fixedeffects model yielded similar results (RR, 0.75; 95% CI, 0.68 to 0.83; P<0.001; heterogeneity I<sup>2</sup>, 18.9%). The lower risk of MACE in intravascular imaging-guided PCI was driven by significantly lower risks of MI (RR, 0.83; 95% CI, 0.70 to 0.97; P=0.019; heterogeneity I<sup>2</sup>, 0.0%) and TVR (RR, 0.70; 95% CI, 0.61 to 0.79; P<0.001; heterogeneity I<sup>2</sup>, 0.0%). Regarding stent thrombosis, observed rates were 0.5% and 1.2% at a weighted median follow-up of 2.0 years for intravascular imaging-guided PCI and angiography-guided PCI groups, respectively (RR, 0.50; 95% CI, 0.32 to 0.78; P=0.002; heterogeneity I<sup>2</sup>, 0.0%). However, there was no difference in the risk of all-cause death between the 2 groups (RR, 0.82; 95% CI, 0.67 to 1.01; P=0.068; heterogeneity  $I^2$ , 0.0%) (Figure 3). To assess the robustness and bias of the main results, additional analyses were performed. Fixed-effects models yielded consistent results with those from the random-effects models for MI, TVR, and stent thrombosis. In the cumulative meta-analysis to evaluate the temporal trend, intravascular imaging-guided PCI consistently showed a lower risk of MACE than angiography-guided PCI over time from 2000 to 2023 (Supplemental Figure 2). No individual study substantially influenced the pooled effect estimate for MACE (Supplemental Figure 3). Funnel plots, supported by Egger's and Begg's tests, indicated no small study bias

for MACE. The adjusted RRs for MACE by trim-and-fill method showed consistent results 1

(RR, 0.75; 95% CI, 0.67 to 0.84; P<0.001) (**Supplemental Figure 4**).

## **Subgroup Analysis**

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

In subgroup analysis according to the all-comers population or patients with complex coronary artery lesions, intravascular imaging-guided PCI consistently showed a lower risk of MACE than angiography-guided PCI. However, the prognostic benefit of the intravascular imaging-guided PCI was relatively higher in patients treated by 2<sup>nd</sup> generation DES than previous types of stents (Interaction P value=0.014) (Figure 4). The prognostic benefit of intravascular imaging-guided PCI over angiography-guided PCI was consistently observed in both stable ischemic heart disease and acute coronary syndrome (Supplemental Figure 5). Other subgroup analyses also showed similar results (Figure 4). Although intravascular imaging-guided PCI marginally reduced the risk of all-cause death in overall meta-analysis, subgroup of the trials with 2<sup>nd</sup> generation DES showed significant reduction of all-cause death in intravascular imaging-guided PCI group than angiography-guided PCI group (RR, 0.77; 95% CI, 0.61 to 0.95; P=0.018; heterogeneity I<sup>2</sup>, 0.0%), which was not seen in the trials with bare metal stent or 1<sup>st</sup> generation DES (Figure 5).

#### **Patient and Public Involvement**

No patient was involved in conceiving the research question, designing of the study, or interpretating the results.

#### **Discussion**

The current updated meta-analysis compared clinical outcomes of intravascular

imaging-guided PCI versus angiography-guided PCI from 24 RCTs available to date. The major findings were as follows. (1) The intravascular imaging-guided PCI significantly reduced the risk of MACE, a composite of all-cause death, MI, or TVR, compared with angiography-guided PCI. (2) The intravascular imaging-guided PCI also significantly reduced MI, TVR, and stent thrombosis, compared with angiography-guided PCI. Although overall meta-analysis showed marginal effect of intravascular imaging-guided PCI regarding all-cause death, subgroup analysis of the trials with 2<sup>nd</sup> generation DES showed significantly reduced risk of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI. (3) The prognostic benefit of intravascular imaging-guided PCI was consistently shown across various subgroups including complex coronary artery lesions and acute coronary syndrome.

## **Current Status of Intravascular Imaging-Guided PCI**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Previous RCTs have reported that intravascular imaging-guided PCI reduced the risk of MACE compared with angiography-guided PCI, largely by lowering the risk of repeat revascularization. 12-14 32 However, those RCTs have not been considered to be definitive due to limited sample size or inclusion of highly selected coronary lesion subsets. In this regard, current practice guidelines recommend the use of intravascular imaging-guided PCI as Class IIa.<sup>12</sup> Furthermore, penetration rate of intravascular imaging in daily practice has been low, although it varies across different healthcare systems or clinical indications of PCI. For example, it was approximately 7.0-9.3% in the United States<sup>33 34</sup> and 27.5-28.6% in South Korea.35

## Prognostic Impact of Intravascular Imaging-Guided PCI

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Since most RCTs had only modest sample sizes to establish clinical benefit of intravascular imaging-guided PCI in terms of hard clinical events such as death, MI, or stent thrombosis, a few observational studies assessed a larger number of patients and showed that intravascular imaging-guided PCI resulted in a lower risk of death or MI than angiographyguided PCI. 33 36-38 Although previous meta-analyses presented similar results, 39 40 inclusion of both observational studies and RCTs would have caused heterogeneity and lowered the evidence level of the results. Recently, 3 large scaled RCTs have been published and showed conflicting results regarding the prognostic benefit of intravascular imaging-guided PCI.<sup>29 30 41</sup> The RENOVATE-COMPLEX-PCI trial evaluated 1,639 patients with complex coronary artery lesions and firstly showed a superiority of imaging-guided PCI using IVUS or OCT over angiography-guided PCI in reducing the hard clinical end point including cardiac death and MI at a median follow-up of 2.1 years (7.7% vs. 12.3%, respectively; HR, 0.64; 95% CI, 0.45-0.89; P=0.008).41 Subsequent OCTOBER trial showed that OCT-guided PCI significantly reduced the risk of target vessel failure at 2 years than angiography-guided PCI in patients with complex bifurcation lesions (10.1% vs. 14.1%, respectively; HR, 0.70; 95% CI, 0.50-0.98; P=0.035).<sup>29</sup> Conversely, ILUMIEN IV trial failed to show significant prognostic benefit of OCT-guided PCI than angiography-guided PCI in patients with diabetes mellitus or complex coronary artery lesions at 2 years (7.4% vs. 8.2%, respectively; HR, 0.90; 95% CI, 0.67-1.19; P=0.45).<sup>30</sup> The current meta-analysis was performed to clarify whether intravascular imagingguided PCI would have prognostic benefit over angiography-guided PCI, especially for hard clinical events such as all-cause death, MI, or stent thrombosis. Compared with previous metaanalyses, 39 40 the current study included only RCTs and evaluated the largest number of randomized patients. Similar to the prior results, intravascular imaging-guided PCI was associated with a lower risk of MACE compared with angiography-guided PCI among all-

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

comers and patients with complex coronary artery lesions. The results suggested that intravascular imaging-guided PCI would prevent 1 MACE event in every 33 patients undergoing PCI. Importantly, it should be noted that intravascular imaging-guided PCI reduced not only the risk of TVR but also the risks of hard clinical events such as MI and stent thrombosis. The I<sup>2</sup> values for all clinical outcomes evaluated in the current study were less than 25%, indicating low heterogeneity among the included trials. Conversely, there was no significant difference in the risk of all-cause mortality between the 2 groups in meta-analysis of overall trials. However, it should be noted that pooled analysis of the trials with 2<sup>nd</sup> generation DES showed significantly reduced risk of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI. Considering that bare metal stent or 1st generation DES are no longer used in contemporary PCI and that the risks of MI and stent thrombosis significantly reduced following intravascular imaging-guided PCI, it would be reasonable to accept survival benefit of intravascular imaging-guided PCI in contemporary practice. Currently ongoing trials will evaluate IVUS-guided PCI in all-comers with complex coronary artery lesions (IMPROVE [NCT04221815] and IVUS-CHIP [NCT04854070]) or unprotected left main disease (OPTIMAL [NCT04111770] and DKCRUSH-VIII [NCT03770650]), or OCT-guided PCI (OCCUPI [NCT03625908]), and these trials will provide additional information on the benefit of intravascular imaging-guided PCI, especially regarding the risk of death after PCI.

## **Future Perspectives of Intravascular Imaging-Guided PCI**

In the current study, the treatment effect of intravascular imaging-guided PCI was consistent regardless of clinical presentation, cardiovascular comorbidities, type of used stents, and presence of complex coronary lesions. However, it should be noted that the effect size of

the intravascular imaging-guided PCI for the risk of MACE was relatively higher in patients

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

with complex coronary artery lesions. These results were in line with the current guidelines which recommend the use of intravascular imaging-guided PCI mainly for complex coronary artery lesions.<sup>1 2</sup> With emerging evidences, further discussion is needed in interventional societies and guidelines committees as to whether intravascular imaging-guided PCI should be upgraded to Class I recommendation for complex coronary artery lesions. As shown in the subgroup analysis, among complex coronary artery lesions, more evidence from RCTs has been accumulated in chronic total occlusion, left main disease, and diffuse long lesion than other complex coronary artery lesions. Integration of ongoing trials and in-depth discussion are also needed to adequately define the complex coronary artery lesion that may benefit the most from intravascular imaging-guided PCI. In addition, it should not be underestimated that intravascular imaging-guided PCI also reduced the risk of MACE in all-comers. Concurrently, efforts should be made to standardize intravascular imaging optimization criteria that are practical, feasible, and prognostically well-validated. Considering low penetration rates of intravascular imaging in daily practice, more efforts need to be made to increase awareness and educate and support practicing interventional cardiologists.<sup>42</sup> Furthermore, cost-effectiveness of intravascular imaging-guided PCI should be clarified to help increase its penetration rate in daily practice. In the current meta-analysis, intravascular imaging-guided PCI significantly reduced the risk of MACE in both stable ischemic heart disease and acute coronary syndrome patients. However, there has been limited evidence from RCT regarding the role of intravascular imaging-guided PCI in acute coronary syndrome. Similarly, there have only been a few RCTs comparing the clinical benefit of OCT-guided PCI over angiography-guided PCI and recent two large scaled trials (ILUMIEN IV and OCTOBER) showed conflicting results.<sup>29 30</sup> To date,

supporting evidence for OCT-guided PCI was mostly derived from RCTs which showed comparable clinical outcomes between IVUS- and OCT-guided PCI.<sup>20</sup> <sup>21</sup> <sup>43</sup> <sup>44</sup> Similarly, subgroup analysis of the current study demonstrated no significant interaction according to the type of intravascular imaging devices, suggesting similar treatment effect between IVUS- and OCT-guided PCI. These results are in line with the recently published OCTIVUS trial which showed comparable clinical outcomes between IVUS-and OCT-guided PCI.<sup>44</sup> Currently ongoing OCCUPI (NCT03625908) trial will test the potential superiority of OCT-guided PCI over angiography-guided PCI. Furthermore, since those trials are enrolling both stable ischemic heart disease and acute coronary syndrome patients, their results will further enrich the evidence supporting the value of intravascular imaging-guided PCI.

#### Limitations

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Some limitations should be acknowledged. First, this meta-analysis included clinically and methodologically diverse studies. Although we included only RCTs to the final analysis and got insignificant statistical inconsistency or heterogeneity, there were some differences in the study design including the enrollment criteria, type of stent used, type of intravascular imaging devices and procedural optimization criteria, follow-up protocols, and adjunctive pharmacotherapy after PCI. Second, the included trials were conducted from 2000 to 2023 and significant changes in practice patterns such as stent technology, PCI technique, and pharmacotherapy should be considered to interpret the results. However, the results from the cumulative meta-analysis imply that treatment effect of intravascular imaging-guided PCI was consistent over 20 years of period. Third, as this is a study-level meta-analysis, data of the individual patients were not included in the analysis, and therefore, we could not adjust for patient-level confounders especially the differences in target lesion complexity. Fourth, this

1 meta-analysis basically composed of 24 RCTs inherently shares the limitations of each trial.

Fifth, we did not use Google Scholar or Web of Science in the initial search strategies, and

some RCTs were added manually. However, same 24 RCTs were selected even after including

these databases in search strategies and the current meta-analysis included the largest number

of RCTs than previously conducted meta-analyses. Sixth, as current study included only a small

number of patients with ST-segment elevation MI, caution is needed to extrapolate the results

to patients with ST-segment elevation MI.

#### Conclusion

2

3

4

5

6

7

8

9

10

11

12

13

Compared to angiography-guided PCI, intravascular imaging-guided PCI was associated with a reduced the risk of MACE by lowering the risk of MI, TVR, and stent thrombosis. Pooled analysis of trials with 2<sup>nd</sup> generation DES showed significantly lower risk of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI.

Acknowledgment: None.

#### **Contributors**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

DH contributed to conception and design of the work, acquisition, analysis, interpretation of data for the work, drafting of the manuscript. WK contributed to acquisition, analysis, and interpretation of data for the work. SHL contributed to the conception of data for the work, interpretation of data for the work, and critical revision of the manuscript. JML contributed to the conception and design conception and design of the work, acquisition, analysis, interpretation of data for the work, and drafting of the manuscript. All other authors contributed to interpretation of data for the work, and critical revision of the manuscript. All authors approved the final version to be published. The guarantors (DH, WK, and JML) accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding authors (SHL and JML) attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: None

#### **Competing interests**

Dr. Joo Myung Lee received an Institutional Research Grant from Abbott Vascular, Boston Scientific, Philips Volcano, Terumo Corporation, Zoll Medical, and Donga-ST. Prof. Joo-Yong Hahn received an Institutional Research Grant from National Evidence-based Healthcare Collaborating Agency, Ministry of Health & Welfare, Korea, Abbott Vascular, Biosensors, Boston Scientific, Daiichi Sankyo, Donga-ST, Hanmi Pharmaceutical, and Medtronic Inc. Prof. Hyeon-Cheol Gwon received an Institutional Research Grant from Boston

1

6

8

9

11

12

14

15

16

17

19

20

21

22

Scientific, Genoss, and Medtronic Inc. All other authors declare that there are no competing interests to declare. 2 3 Ethical approval: Not required. 4 5 **Data Sharing** 7 Original data used in the current meta-analysis including the analytic codes will be shared upon reasonable request. Any relevant inquiry should be emailed to Dr. Joo Myung Lee (Email: drone80@hanmail.net). 10 The lead author (JML) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted, and that any discrepancies from the study as planned have been explained. 13 Dissemination to participants and related patient and public communities There are no plans to disseminate the results to the individual study participants or the relevant patient community. **Copyright/License for Publication** 18 The Corresponding Author (JML) has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i)

publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution

- into other languages, create adaptations, reprints, include within collections and create 1
- 2 summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s)
- 3 based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the
- inclusion of electronic links from the Contribution to third party material where-ever it may be 4
- located; and, vi) licence any third party to do any or all of the above. 5

#### References

- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87-165. doi:10.1093/eurheartj/ehy394
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;145:e18-e114. doi:10.1161/cir.0000000000001038
- Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;293:2126-30. doi:10.1001/jama.293.17.2126
- Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. *Circ Cardiovasc Interv* 2014;7:768-76.
   doi:10.1161/CIRCINTERVENTIONS.114.001341
- Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. *Lancet* 2015;386:702-13. doi:10.1016/S0140-6736(15)61220-X
- Raber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *Eur Heart J* 2018;39:3281-300. doi:10.1093/eurheartj/ehy285
- Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. *Circulation* 2000;102:523-30. doi:10.1161/01.cir.102.5.523
- Frey AW, Hodgson JM, Muller C, Bestehorn HP, Roskamm H. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary Ultrasound-guided PTCA and Stenting (SIPS) trial. *Circulation* 2000;102:2497-502. doi:10.1161/01.cir.102.20.2497
- Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). *Circulation* 2001;104:1343-9. doi:10.1161/hc3701.096064
- Oemrawsingh PV, Mintz GS, Schalij MJ, et al. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP Study). *Circulation* 2003;107:62-7. doi:10.1161/01.cir.0000043240.87526.3f
- Russo RJ, Silva PD, Teirstein PS, et al. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). *Circ Cardiovasc Interv* 2009;2:113-23. doi:10.1161/CIRCINTERVENTIONS.108.778647
- Jakabcin J, Spacek R, Bystron M, et al. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. *Catheter Cardiovasc Interv* 2010;75:578-83. doi:10.1002/ccd.22244
- Chieffo A, Latib A, Caussin C, et al. A prospective, randomized trial of intravascularultrasound guided compared to angiography guided stent implantation in complex

- 1 coronary lesions: the AVIO trial. *Am Heart J* 2013;165:65-72. doi:10.1016/j.ahj.2012.09.017
- Kim JS, Kang TS, Mintz GS, et al. Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses. *JACC Cardiovasc Interv* 2013;6:369-76. doi:10.1016/j.jcin.2012.11.009
- Kim BK, Shin DH, Hong MK, et al. Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation: Randomized Study. *Circ Cardiovasc Interv* 2015;8:e002592. doi:10.1161/CIRCINTERVENTIONS.115.002592
- Tan Q, Wang Q, Liu D, Zhang S, Zhang Y, Li Y. Intravascular ultrasound-guided unprotected left main coronary artery stenting in the elderly. *Saudi Med J* 2015;36:549-53. doi:10.15537/smj.2015.5.11251
- Tian NL, Gami SK, Ye F, et al. Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. *EuroIntervention* 2015;10:1409-17. doi:10.4244/EIJV10I12A245
- 18 Kim JS, Shin DH, Kim BK, et al. Randomized comparison of stent strut coverage 18 following angiography- or optical coherence tomography-guided percutaneous 19 20 coronary intervention. Rev Esp Cardiol (Engl Ed) 2015;68:190-7. doi:10.1016/j.rec.2014.07.025 21
- Antonsen L, Thayssen P, Maehara A, et al. Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non-ST-Segment-Elevation Myocardial Infarction (OCTACS) Trial: Difference in Strut Coverage and Dynamic Malapposition Patterns at 6 Months. *Circ Cardiovasc* Interv 2015;8:e002446. doi:10.1161/CIRCINTERVENTIONS.114.002446
- 27 20 Ali ZA, Maehara A, Genereux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet* 2016;388:2618-30 28. doi:10.1016/S0140-6736(16)31922-5
- Ali ZA, Karimi Galougahi K, Maehara A, et al. Outcomes of optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation: one-year results from the ILUMIEN III: OPTIMIZE PCI trial. *EuroIntervention* 2021;16:1085-91. doi:10.4244/EIJ-D-20-00498
- Meneveau N, Souteyrand G, Motreff P, et al. Optical Coherence Tomography to
  Optimize Results of Percutaneous Coronary Intervention in Patients with Non-STElevation Acute Coronary Syndrome: Results of the Multicenter, Randomized
  DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting).

  Circulation 2016;134:906-17. doi:10.1161/CIRCULATIONAHA.116.024393
- Kala P, Cervinka P, Jakl M, et al. OCT guidance during stent implantation in primary PCI: A randomized multicenter study with nine months of optical coherence tomography follow-up. *Int J Cardiol* 2018;250:98-103. doi:10.1016/j.ijcard.2017.10.059
- Liu XM, Yang ZM, Liu XK, et al. Intravascular ultrasound-guided drug-eluting stent implantation for patients with unprotected left main coronary artery lesions: A single-center randomized trial. *Anatol J Cardiol* 2019;21:83-90.

47 doi:10.14744/AnatolJCardiol.2018.21447

- Hong SJ, Mintz GS, Ahn CM, et al. Effect of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation: 5-Year Follow-Up of the IVUS-XPL Randomized Trial. *JACC Cardiovasc Interv* 2020;13:62-71. doi:10.1016/j.jcin.2019.09.033
- Chamie D, Costa JR, Jr., Damiani LP, et al. Optical Coherence Tomography Versus 4 26 5 Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary 6 Interventions: The iSIGHT Randomized Trial. Circ Cardiovasc Interv 2021;14:e009452. doi:10.1161/CIRCINTERVENTIONS.120.009452 7
- Gao XF, Ge Z, Kong XQ, et al. 3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.

  JACC Cardiovasc Interv 2021;14:247-57. doi:10.1016/j.jcin.2020.10.001
- Neleman T, van Zandvoort LJC, Tovar Forero MN, et al. FFR-Guided PCI Optimization Directed by High-Definition IVUS Versus Standard of Care: The FFR REACT Trial. *JACC Cardiovasc Interv* 2022;15:1595-607. doi:10.1016/j.jcin.2022.06.018
- Holm NR, Andreasen LN, Neghabat O, et al. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. *N Engl J Med* 2023 doi:10.1056/NEJMoa2307770
- Ali ZA, Landmesser U, Maehara A, et al. Optical Coherence Tomography-Guided versus Angiography-Guided PCI. *N Engl J Med* 2023 doi:10.1056/NEJMoa2305861
- Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *Jama* 2015;313:1657-65. doi:10.1001/jama.2015.3656
- Hong SJ, Kim BK, Shin DH, et al. Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. *JAMA* 2015;314:2155-63. doi:10.1001/jama.2015.15454
- Mentias A, Sarrazin MV, Saad M, et al. Long-Term Outcomes of Coronary Stenting
  With and Without Use of Intravascular Ultrasound. *JACC Cardiovasc Interv*26 2020;13:1880-90. doi:10.1016/j.jcin.2020.04.052
- Park DY, Vemmou E, An S, et al. Trends and impact of intravascular ultrasound and optical coherence tomography on percutaneous coronary intervention for myocardial infarction. *Int J Cardiol Heart Vasc* 2023;45:101186. doi:10.1016/j.ijcha.2023.101186
- Shin DH, Kang HJ, Jang JS, et al. The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. *Korean Circ J* 2019;49:1136-51. doi:10.4070/kcj.2018.0413
- Witzenbichler B, Maehara A, Weisz G, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. *Circulation* 2014;129:463-70. doi:10.1161/CIRCULATIONAHA.113.003942
- Kinnaird T, Johnson T, Anderson R, et al. Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stem PCI: An Analysis From the British Cardiovascular Intervention Society Database. *JACC Cardiovasc Interv* 2020;13:346-57. doi:10.1016/j.jcin.2019.10.007
- Choi KH, Song YB, Lee JM, et al. Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures. *JACC Cardiovasc Interv* 2019;12:607-20. doi:10.1016/j.jcin.2019.01.227
- Buccheri S, Franchina G, Romano S, et al. Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary

1	Intervention With Stent Imp	olantation: A S	Systematic Rev	iew and	Bayesian No	etwork
2	Meta-Analysis of 31 Stud	dies and 17	,882 Patients.	<i>JACC</i>	Cardiovasc	Interv
3	2017;10:2488-98. doi:10.101	6/i.icin.2017.	08.051			

- Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, Osborn EA.
  Intravascular Ultrasound Imaging-Guided Versus Coronary Angiography-Guided
  Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. *J Am Heart Assoc* 2020;9:e013678. doi:10.1161/JAHA.119.013678
- Lee JM, Choi KH, Song YB, et al. Intravascular Imaging-Guided or Angiography-Guided Complex PCI. *N Engl J Med* 2023;388:1668-79. doi:10.1056/NEJMoa2216607
- Choi KH, Lee SY, Song YB, et al. Prognostic Impact of Operator Experience and IVUS
   Guidance on Long-Term Clinical Outcomes After Complex PCI. *JACC Cardiovasc Interv* 2023;16:1746-58. doi:10.1016/j.jcin.2023.04.022
- Kubo T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. *Eur Heart J* 2017;38:3139-47. doi:10.1093/eurheartj/ehx351
- Kang DY, Ahn JM, Yun SC, et al. Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial. *Circulation* 2023 doi:10.1161/CIRCULATIONAHA.123.066429

Figure Legends

1

5

6

7

9

10

13

14

15

16

17

18

19

20

21

22

23

24

2 Figure 1. Flow Diagram of Study Selection

3 The study flow diagram was depicted following the guideline of Preferred Reporting Items for

4 Systematic Reviews and Meta-Analyses (PRISMA).

Figure 2. Meta-Analysis Comparing Major Adverse Cardiac Event Between

Intravascular Imaging vs. Angiography-Guided PCI

8 Forest plots comparing major adverse cardiac event, a composite of all-cause death, myocardial

infarction, and target vessel revascularization between intravascular imaging-guided and

angiography-guided PCI. RRs with 95% CIs are displayed for individual studies and the pooled

11 overall effect.

12 Abbreviations: AIR-CTO, Angiographic and clinical comparisons of intravascular ultrasound-

versus angiography-guided drug-eluting stent implantation for patients with chronic total

occlusion lesions; AVID, Angiography Versus Intravascular ultrasound-Directed stent

placement; AVIO, Angiography Vs. IVUS Optimization; CRUISE, Can Routine Ultrasound

Influence Stent Expansion; CI, indicates confidence interval; CTO-IVUS, Chronic Total

Occlusion InterVention with drUg-eluting Stents guided by IVUS; **DOCTORS**, Does Optical

Coherence Tomography Optimize Results of Stenting; FFR-REACT, Fractional flow reserve

guided percutaneous coronary intervention optimization directed by high-definition

intravascular ultrasound versus standard of care; HOME DES IVUS, Long-Term Health

Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting

Stents with or without the IVUS Guidance; iSIGHT, Optical Coherence Tomography Versus

Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions;

IVUS-XPL, Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime

1 Stents in Long Lesions; OCTACS, Optical Coherence Tomography Guided Percutaneous

Coronary Intervention With Nobori Stent Implantation in Patients With Non ST Segment 2

Elevation Myocardial Infarction; OCTOBER, European Trial on Optical Coherence

Tomography Optimized Bifurcation Event Reduction; **OPTICUS**, OPTimization with ICUS

to reduce stent restenosis; RENOVATE COMPLEX-PCI, Randomized Controlled Trial of

Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After

7 Complex Percutaneous Coronary Intervention; PCI, percutaneous coronary intervention;

RESET, Real Safety and Efficacy of a 3-Month Dual Antiplatelet Therapy Following

Zotarolimus-Eluting Stents Implantation; ROBUST, Comparison of Biolimus A9 and

Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction; 10

11 RR, relative risk; SIPS, Strategy for Intracoronary Ultrasound-Guided PTCA and Stenting;

TULIP, Thrombocyte activity evaluation and effects of Ultrasound guidance in Long 12

Intracoronary stent Placement; and ULTIMATE, Intravascular Ultrasound Guided Drug 13

Eluting Stents Implantation in "All-Comers" Coronary Lesions. 14

#### 16 Figure 3. Meta-Analysis Comparing Clinical Outcomes Between Intravascular Imaging

#### vs. Angiography-Guided PCI 17

3

4

5

6

8

9

15

19

23

24

Forest plots comparing individual clinical outcomes between intravascular imaging-guided and 18

angiography-guided PCI. RRs with 95% CIs are displayed for individual studies and the pooled

20 overall effect. (A) all-cause death, (B) myocardial infarction, (C) target vessel revascularization,

and (D) stent thrombosis. 21

22 Abbreviations are as in Figure 2.

## Figure 4. Subgroup Analysis

- 1 Forest plots of subgroup analysis comparing major adverse cardiac event, a composite of all-
- 2 cause death, myocardial infarction, and target vessel revascularization between intravascular
- 3 imaging-guided and angiography-guided PCI. RRs with 95% CIs are displayed for individual
- studies and the pooled overall effect. 4
- Abbreviations are as in Figure 2. 5

- Figure 5. Meta-Analysis Comparing Death Between Intravascular Imaging vs. Angio-7
- 8 **Guided Optimization Stratified by Stent Type**
- Forest plots comparing all-cause death between intravascular imaging-guided and 9
- 10 angiography-guided PCI according to type of used stents. RRs with 95% CIs are displayed for
- 11 individual studies and the pooled overall effect.
- Abbreviations are as in Figure 2. 12

**Table 1. Baseline Characteristics of the Included Trials** 

T 1	Enroll	Median		Imaging-	Angiography-	Proportion of		Stent Type
Trial	Period	Follow-up (year)	Study Population	guided PCI (no)	guided PCI (no)	Imaging Devices (%) IVUS OCT		
CRUISE	1996-1997	0.75	All patients undergoing PCI	270	229	100	0	BMS
SIPS	1996-1996	2	All patients undergoing PCI	121	148	100	0	BMS
OPTICUS	1996-1998	∠ 1	All patients undergoing PCI	273	275	100	0	BMS
	1990-1998	1		73	71	100	0	BMS
TULIP	1998-2001	1 1	Long lesion				-	
AVID		1 1.5	All patients undergoing PCI	369	375	100	0	BMS
HOME DES IVUS	2004-2005	1.5	Various complex lesions only	105	105	100	0	1st Gen DES
AVIO	2008-2009	2	Various complex lesions only	142	142	100	0	1st Gen DES
Kim et al. (RESET substudy)	2009-2012	1	Long lesion	269	274	100	0	2 <sup>nd</sup> Gen DES
CTO-IVUS	2012-2013	1	Chronic total occlusion	201	201	100	0	2 <sup>nd</sup> Gen DES
AIR-CTO	2010-2011	2	Chronic total occlusion	115	115	100	0	2 <sup>nd</sup> Gen DES
Tan et al.	2009-2012	2	Left main	61	62	100	0	2 <sup>nd</sup> Gen DES
Kim et al.	2011-2012	1	All patients undergoing PCI	58	59	0	100	2 <sup>nd</sup> Gen DES
OCTACS	2011-2013	0.5	Non ST-segment elevation MI	50	50	0	100	2 <sup>nd</sup> Gen DES
DOCTORS	2013-2015	0.5	All patients undergoing PCI	120	120	0	100	2 <sup>nd</sup> Gen DES
ROBUST	2011-2012	0.75	ST-segment elevation MI	105	96	0	100	2 <sup>nd</sup> Gen DES
Liu et al.	2010-2015	1	Left main	167	169	100	0	2 <sup>nd</sup> Gen DES
IVUS-XPL	2010-2014	5	Long lesion	700	700	100	0	2 <sup>nd</sup> Gen DES
ILUMIEN III	2015-2016	1	All patients undergoing PCI	289	142	47	53	2 <sup>nd</sup> Gen DES
ULTIMATE	2014-2017	3	All patients undergoing PCI	724	724	100	0	2 <sup>nd</sup> Gen DES
iSIGHT	2015-2016	1	All patients undergoing PCI	101	49	50	50	2 <sup>nd</sup> Gen DES
FFR-REACT	2017-2020	1	All patients undergoing PCI	145	146	100	0	2 <sup>nd</sup> Gen DES
RENOVATE COMPLEX-PCI	2018-2021	2.1	Various complex lesions only	1092	547	74	26	2 <sup>nd</sup> Gen DES
ILUMIEN IV	2018-2020	2	Various complex lesions only and diabetes mellitus	1233	1254	0	100	2 <sup>nd</sup> Gen DES
OCTOBER	2017-2022	2	True bifurcation	600	601	0	100	2 <sup>nd</sup> Gen DES

Abbreviations: BMS, bare metal stent; DES, drug-eluting stent; Gen, generation; IVUS, intravascular ultrasound; MI, myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.

Figure 1. Flow Diagram of Study Selection.





Figure 2. Meta-Analysis Comparing Major Adverse Cardiac Event Between Intravascular Imaging vs. Angio-Guided Optimization

Trial	Publication Year		RR (95% CI)	Imaging Event/Total	Angiography Event/Total	Weight (%)
CRUISE	2000	•	0.70 (0.48, 1.01)	42/270	51/229	6.80
SIPS	2000	-	0.82 (0.59, 1.16)	37/121	55/148	7.59
OPTICUS	2001		1.07 (0.75, 1.52)	52/273	49/275	7.24
TULIP	2003	<del>- ■ ;</del> _	0.46 (0.22, 0.95)	9/73	19/71	2.23
AVID	2009	•	0.99 (0.73, 1.33)	68/369	70/375	8.93
HOME DES IVUS	2010		0.92 (0.42, 1.98)	11/105	12/105	1.98
AVIO	2013	-	0.73 (0.45, 1.17)	24/142	33/142	4.66
Kim et al. (RESET substudy)	2013	<del> </del>	0.61 (0.30, 1.23)	12/269	20/274	2.39
CTO-IVUS	2015	<del></del>	0.36 (0.13, 0.97)	5/201	14/201	1.21
AIR-CTO	2015	<del></del>	0.86 (0.54, 1.38)	25/115	29/115	4.71
Tan et al.	2015		0.48 (0.22, 1.03)	8/61	17/62	2.02
OCTACS	2015		0.20 (0.01, 4.06)	0/50	2/50	0.14
Kim et al.	2015	<del></del>	0.68 (0.12, 3.91)	2/58	3/59	0.41
DOCTORS	2016	<del></del>	1.50 (0.26, 8.82)	3/120	2/120	0.40
ROBUST	2018	<del>_</del>	4.57 (0.54, 38.43)	5/105	1/96	0.28
Liu et al.	2019	•	0.60 (0.37, 0.97)	22/167	37/169	4.49
IVUS-XPL (5Y)	2020		0.51 (0.35, 0.76)	36/700	70/700	6.30
ILUMIEN III	2021	<del>:</del> •	1.21 (0.62, 2.36)	27/289	11/142	2.55
ULTIMATE (3Y)	2021	-	0.62 (0.44, 0.88)	47/724	76/724	7.35
iSIGHT	2021	<del></del>	0.97 (0.25, 3.72)	6/101	3/49	0.69
FFR-REACT	2022		0.86 (0.30, 2.51)	6/145	7/146	1.08
RENOVATE COMPLEX-PCI	2023		0.63 (0.46, 0.88)	76/1092	60/547	8.17
ILUMIEN IV	2023	-	0.90 (0.69, 1.19)	88/1233	99/1254	9.92
OCTOBER	2023	•	0.71 (0.52, 0.97)	59/600	83/601	8.46
Overall Random Effects Mo	del	•	0.75 (0.67, 0.84)	670/7383	823/6654	100.00
	Test of Overall Effec	t : RR 0.75 (95% CI 0.67-0.84), P < 0.00	1, Heterogeneity I <sup>2</sup> = 1	8.9%		
		.1 .2 .5 1 2 5 10				

Imaging-guided PCI Better Angiography-guided PCI Better


Figure 3. Meta-Analysis Comparing Clinical Outcomes Between Intravascular Imaging vs. Angiography-Guided PCI

#### A. Death



# C. Target Vessel Revascularization

Imaging-guided PCI Better



Angiography-guided PCI Better

# **B.** Myocardial Infarction

<u>-</u>		•     •     •	=		0.2 0.6 0.1 1.3 0.2 0.8	15 (0.59, 2 20 (0.02, 1 30 (0.22, 1 19 (0.02, 1 34 (0.75, 2 25 (0.03, 2 33 (0.37, 1	.67) .64) .62) .39) .20) .87)	19/270 1/121 6/273 1/73 25/369 1/105 10/142 0/269	14/229 6/148 10/275 5/71 19/375 4/105 12/142 2/274	5.71 0.58 2.55 0.57 7.59 0.54 3.91 0.28
			=		0.6 0.1 1.3 0.2 0.8 0.2	60 (0.22, 1 19 (0.02, 1 34 (0.75, 2 25 (0.03, 2 33 (0.37, 1 20 (0.01, 4	.64) .62) .39) .20) .87)	6/273 1/73 25/369 1/105 10/142 0/269	10/275 5/71 19/375 4/105 12/142	2.55 0.57 7.59 0.54 3.91
<u>=</u>		-	_		0.1 1.3 0.2 0.8 0.2	19 (0.02, 1. 34 (0.75, 2. 25 (0.03, 2. 33 (0.37, 1. 20 (0.01, 4.	.62) (.39) (.20) (.87) (.22)	1/73 25/369 1/105 10/142 0/269	5/71 19/375 4/105 12/142	0.57 7.59 0.54 3.91
<u></u>			_		1.3 0.2 0.8 0.2	34 (0.75, 2 25 (0.03, 2 33 (0.37, 1 20 (0.01, 4	(.39) (.20) (.87) (.22)	25/369 1/105 10/142 0/269	19/375 4/105 12/142	7.59 0.54 3.91
<u> </u>			=		0.2 0.8 0.2	25 (0.03, 2 33 (0.37, 1 20 (0.01, 4	.20) .87) .22)	1/105 10/142 0/269	4/105 12/142	0.54 3.91
=	-	=	=		0.8	33 (0.37, 1. 20 (0.01, 4	.87)	10/142 0/269	12/142	3.91
=	-	-	_		0.2	20 (0.01, 4	.22)	0/269		
			_			The state of the s			2/274	0.20
			_		0.7	0.0004 4	441		2,217	0.20
					٠	20 (0.01, 4	.14)	0/201	2/201	0.28
·					1.3	33 (0.72, 2	.47)	20/115	15/115	6.67
			_		0.5	51 (0.05, 5	.46)	1/61	2/62	0.45
	-				1.0	0 (0.06, 15	5.80)	1/120	1/120	0.33
· -	-		•		4.5	8 (0.22, 94	4.12)	2/105	0/96	0.28
	-	-			0.8	4 (0.47, 1	.48)	19/167	23/169	7.87
_					0.6	7 (0.19, 2	.35)	4/700	6/700	1.60
		•	-10		1.1	5 (0.30, 4	.37)	7/289	3/142	1.42
	-				0.4	7 (0.19, 1	.14)	7/724	15/724	3.20
_		×			0.4	0 (0.13, 1	.26)	5/101	6/49	1.97
_	-	_			0.5	8 (0.17, 1	.92)	4/145	7/146	1.75
		ŀ			0.6	7 (0.43, 1	.05)	43/1092	32/547	12.80
	-	ŧ.			0.8	1 (0.57, 1	.13)	57/1233	72/1254	22.21
	-				0.9	0 (0.62, 1	.32)	46/600	51/601	17.43
	<b>†</b>				0.8	3 (0.70, 0	.97)	279/7383	307/6654	100.00
erall Effect : RR	0.83 (95	% CI (	).70-0.9	97), P = 0	).019, Hetero	geneity l	² = 0.	0%		
	.1 .2		.1 .2 .5 1 2	.1 .2 .5 1 2 5	.1 .2 .5 1 2 5 10	0.8 0.6 0.6 0.4 0.4 0.5 0.6 0.8 0.9 0.9 0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	0.84 (0.47, 1 0.67 (0.19, 2 1.15 (0.30, 4 0.47 (0.19, 1 0.40 (0.13, 1 0.58 (0.17, 1 0.67 (0.43, 1 0.81 (0.57, 1 0.90 (0.62, 1 0.83 (0.70, 0 erall Effect: RR 0.83 (95% Cl 0.70-0.97), P = 0.019, Heterogeneity F	0.84 (0.47, 1.48) 0.67 (0.19, 2.35) 1.15 (0.30, 4.37) 0.47 (0.19, 1.14) 0.40 (0.13, 1.26) 0.58 (0.17, 1.92) 0.67 (0.43, 1.05) 0.81 (0.57, 1.13) 0.90 (0.62, 1.32) 0.83 (0.70, 0.97)  erall Effect: RR 0.83 (95% CI 0.70-0.97), P = 0.019, Heterogeneity I² = 0.019	0.84 (0.47, 1.48) 19/167 0.67 (0.19, 2.35) 4/700 1.15 (0.30, 4.37) 7/289 0.47 (0.19, 1.14) 7/724 0.40 (0.13, 1.26) 5/101 0.58 (0.17, 1.92) 4/145 0.67 (0.43, 1.05) 43/1092 0.81 (0.57, 1.13) 57/1233 0.90 (0.62, 1.32) 46/600 0.83 (0.70, 0.97) 279/7383 erall Effect: RR 0.83 (95% CI 0.70-0.97), P = 0.019, Heterogeneity I° = 0.0%	0.84 (0.47, 1.48) 19/167 23/169 0.67 (0.19, 2.35) 4/700 6/700 1.15 (0.30, 4.37) 7/289 3/142 0.47 (0.19, 1.14) 7/724 15/724 0.40 (0.13, 1.26) 5/101 6/49 0.58 (0.17, 1.92) 4/145 7/146 0.67 (0.43, 1.05) 43/1092 32/547 0.81 (0.57, 1.13) 57/1233 72/1254 0.90 (0.62, 1.32) 46/600 51/601 0.83 (0.70, 0.97) 279/7383 307/6654  erall Effect : RR 0.83 (95% CI 0.70-0.97), P = 0.019, Heterogeneity I² = 0.0%

#### D. Stent Thrombosis

Trial	Publication Year		RR (95% CI)	Imaging Event/Total	Angiography Event/Total	Weight (%)
AVID	2009		1.27 (0.34, 4.69)	5/369	4/375	11.39
HOME DES IVUS	2010	<del>-  ≖</del>	0.67 (0.19, 2.29)	4/105	6/105	12.73
RESET	2013		1.02 (0.06, 16.20)	1/269	1/274	2.54
CTO-IVUS	2015	<del></del>	0.14 (0.01, 2.75)	0/201	3/201	2.22
AIR-CTO	2015	•	0.14 (0.02, 1.14)	1/115	7/115	4.50
OCTACS	2015	•	0.33 (0.01, 7.99)	0/50	1/50	1.93
Kim et al. (RESET substudy)	2015	• • •	0.34 (0.01, 8.15)	0/58	1/59	1.92
ROBUST	2018		0.91 (0.06, 14.42)	1/105	1/96	2.56
Liu et al.	2019		0.40 (0.08, 2.06)	2/167	5/169	7.36
IVUS-XPL (5Y)	2020	<del>-    </del>	1.00 (0.14, 7.08)	2/700	2/700	5.08
ILUMIEN III	2021		1.48 (0.06, 36.09)	1/289	0/142	1.91
ULTIMATE (3Y)	2021	•	0.13 (0.02, 1.00)	1/724	8/724	4.51
FFR-REACT	2022 -	•	0.34 (0.01, 8.17)	0/145	1/146	1.91
RENOVATE COMPLEX-PCI	2023	•	0.13 (0.01, 1.12)	1/1092	4/547	4.06
ILUMIEN IV	2023		0.36 (0.14, 0.91)	6/1233	17/1254	22.62
OCTOBER	2023	+ +	1.00 (0.29, 3.44)	5/600	5/601	12.76
Overall Random Effects Mo	odel	•	0.50 (0.32, 0.78)	30/6443	66/5727	100.00
	Test of Overall	Effect : RR 0.50 (95% CI 0.32-0.78), F	P = 0.002, Heterogeneity I <sup>2</sup> =	0.0%		

.5 1 2 5 10

Angiography-guided PCI Better

.1 .2

Imaging-guided PCI Better

Figure 4. Subgroup Analysis





Figure 5. Meta-Analysis Comparing Death Between Intravascular Imaging vs. Angio-Guided Optimization Stratified by Stent Type



Imaging-guided PCI Better

Angiography-guided PCI Better